Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24

Benzinga Newsdesk www.benzinga.com Negative 84.3%

Neg 84.3% Neu 0% Pos 0%

Piper Sandler analyst Kelsey Goodwin downgrades Tango Therapeutics (NASDAQ:TNGX) from Overweight to Neutral and raises the price target from $16 to $24.